➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Colorcon
McKesson
Boehringer Ingelheim
AstraZeneca

Last Updated: August 7, 2020

DrugPatentWatch Database Preview

PLAZOMICIN SULFATE - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for plazomicin sulfate and what is the scope of patent protection?

Plazomicin sulfate is the generic ingredient in one branded drug marketed by Cipla Usa and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Plazomicin sulfate has twenty-eight patent family members in twenty-one countries.

Two suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for PLAZOMICIN SULFATE
International Patents:28
US Patents:4
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 2
Bulk Api Vendors: 1
DailyMed Link:PLAZOMICIN SULFATE at DailyMed
Generic filers with tentative approvals for PLAZOMICIN SULFATE
Applicant Application No. Strength Dosage Form
  Start Trial  Start TrialEQ 500MG BASE/10ML (EQ 50MG BASE/ML)SOLUTION;INTRAVENOUS

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

US Patents and Regulatory Information for PLAZOMICIN SULFATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cipla Usa ZEMDRI plazomicin sulfate SOLUTION;INTRAVENOUS 210303-001 Jun 25, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Cipla Usa ZEMDRI plazomicin sulfate SOLUTION;INTRAVENOUS 210303-001 Jun 25, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Cipla Usa ZEMDRI plazomicin sulfate SOLUTION;INTRAVENOUS 210303-001 Jun 25, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Cipla Usa ZEMDRI plazomicin sulfate SOLUTION;INTRAVENOUS 210303-001 Jun 25, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Harvard Business School
Merck
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.